These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 11772158

  • 1. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M, Plosker GL.
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL, Hurst M.
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [Abstract] [Full Text] [Related]

  • 3. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [Abstract] [Full Text] [Related]

  • 4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
    Health Technol Assess; 2001 Mar; 5(32):1-195. PubMed ID: 12065068
    [Abstract] [Full Text] [Related]

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Mar; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A, Trippoli S, Becagli P, Tendi E.
    Cancer; 1996 Dec 01; 78(11):2366-73. PubMed ID: 8941008
    [Abstract] [Full Text] [Related]

  • 9. Pharmacoeconomic profile of taxanes in advanced ovarian cancer.
    Messori A, Trippoli S.
    Anticancer Drugs; 1998 Nov 01; 9(10):909-16. PubMed ID: 9890702
    [Abstract] [Full Text] [Related]

  • 10. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care.
    Acta Oncol; 2001 Nov 01; 40(2-3):340-60. PubMed ID: 11441940
    [Abstract] [Full Text] [Related]

  • 11. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM, Wiseman LR.
    Pharmacoeconomics; 1998 Oct 01; 14(4):447-59. PubMed ID: 10344911
    [Abstract] [Full Text] [Related]

  • 12. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Oct 01; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J.
    Health Technol Assess; 2000 Oct 01; 4(17):1-113. PubMed ID: 11074389
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
    Wiseman LR, Spencer CM.
    Drugs Aging; 1998 Apr 01; 12(4):305-34. PubMed ID: 9571394
    [Abstract] [Full Text] [Related]

  • 16. The pharmacoeconomics of cancer therapies.
    Bishop JF, Macarounas-Kirchman K.
    Semin Oncol; 1997 Dec 01; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Havrilesky LJ, Pokrzywinski R, Revicki D, Higgins RV, Nycum LR, Kohler MF, Berchuck A, Myers ER, Secord AA.
    Cancer; 2012 Jan 15; 118(2):386-91. PubMed ID: 21598242
    [Abstract] [Full Text] [Related]

  • 18. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
    Dranitsaris G, Elia-Pacitti J, Cottrell W.
    Pharmacoeconomics; 2004 Jan 15; 22(6):375-87. PubMed ID: 15099123
    [Abstract] [Full Text] [Related]

  • 19. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
    Poonawalla IB, Parikh RC, Du XL, VonVille HM, Lairson DR.
    Pharmacoeconomics; 2015 Nov 15; 33(11):1155-85. PubMed ID: 26072142
    [Abstract] [Full Text] [Related]

  • 20. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
    Elit LM, Gafni A, Levine MN.
    J Clin Oncol; 1997 Feb 15; 15(2):632-9. PubMed ID: 9053487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.